ReviewJournal of physiology and biochemistry2016
Anti-obesity effects of resveratrol: comparison between animal models and humans.
Review in Journal of physiology and biochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- Resveratrol Prevents Weight Gain, Counteracts Visceral Adipose Tissue Dysfunction, and Improves Hypothalamic Leptin Sensitivity in Diet-Induced Obese Rats.Molecular nutrition & food research · 2025Article
- Combined Potential of Orlistat with Natural Sources and Their Bioactive Compounds Against Obesity: A Review.Molecules (Basel, Switzerland) · 2025Review
- Changes in brown adipose tissue induced by resveratrol and its analogue pterostilbene in rats fed with a high-fat high-fructose diet.Journal of physiology and biochemistry · 2024Article
- Biological function of resveratrol and its application in animal production: a review.Journal of animal science and biotechnology · 2023Review
- Resveratrol Inhibits Proliferation and Differentiation of Porcine Preadipocytes by a Novel LincRNA-ROFM/miR-133b/AdipoQ Pathway.Foods (Basel, Switzerland) · 2022Article
- Editorial Special Issue: 2020 consortium for trans-pyrenean investigations on obesity and diabetes.Journal of physiology and biochemistry · 2022Article
- Enhancing Bioavailability of Nutraceutically Used Resveratrol and Other Stilbenoids.Nutrients · 2021Review
- Targeting Energy Expenditure-Drugs for Obesity Treatment.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Targeting Stem Cells in Chronic Inflammatory Diseases.Advances in experimental medicine and biology · 2021Review
- Polyphenols for diabetes associated neuropathy: Pharmacological targets and clinical perspective.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2019Review
- Resveratrol Modulates and Reverses the Age-Related Effect on Adenosine-Mediated Signalling in SAMP8 Mice.Molecular neurobiology · 2019Article
- Resveratrol Anti-Obesity Effects: Rapid Inhibition of Adipocyte Glucose Utilization.Antioxidants (Basel, Switzerland) · 2019Article
- The Effects of Resveratrol in the Treatment of Metabolic Syndrome.International journal of molecular sciences · 2019Review
- Past, Present and Future Anti-Obesity Effects of Flavin-Containing and/or Copper-Containing Amine Oxidase Inhibitors.Medicines (Basel, Switzerland) · 2019Review
- Deciphering the Anti-obesity Benefits of Resveratrol: The "Gut Microbiota-Adipose Tissue" Axis.Frontiers in endocrinology · 2019Review
- Resveratrol, Metabolic Syndrome, and Gut Microbiota.Nutrients · 2018Review
- Do the Effects of Resveratrol on Thermogenic and Oxidative Capacities in IBAT and Skeletal Muscle Depend on Feeding Conditions?Nutrients · 2018Article
- Resveratrol and Pterostilbene, Two Analogue Phenolic Compounds, Affect Aquaglyceroporin Expression in a Different Manner in Adipose Tissue.International journal of molecular sciences · 2018Article
- Developmental Programming of the Metabolic Syndrome: Can We Reprogram with Resveratrol?International journal of molecular sciences · 2018Review
- The Dietary Antioxidant Piceatannol Inhibits Adipogenesis of Human Adipose Mesenchymal Stem Cells and Limits Glucose Transport and Lipogenic Activities in Adipocytes.International journal of molecular sciences · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of obesity has increased rapidly during recent years and has reached epidemic proportions. As a result, the scientific community is interested in active biomolecules which are naturally present in plants and foodstuffs and may be useful in body weight management. In recent years, polyphenols have made up one of the most frequently studied groups among these molecules. Numerous studies have been carried out on animals to analyse the potential anti-obesity effects of resveratrol, a non-flavonoid polyphenol, and a general consensus concerning the body-fat-lowering effect of this compound exists. By contrast, studies in humans have been few so far. Moreover, in these studies, the effectiveness of resveratrol is low. The aims of the present review are to summarize the results reported so far on this topic and to justify the differences observed between animals and humans. It seems that the reduced response to resveratrol in humans cannot be attributed to the use of lower doses in humans because the doses that induce body-fat-lowering effects in rodents are in the same range as those used in human studies. With regard to the experimental period length, treatments were longer in animal studies than in human studies. This can be one of the reasons contributing to the reduced responses observed in humans. Moreover, animals used in the reported studies are young while volunteers participating in human studies are adults, suggesting that resveratrol may be more efficient in young individuals. In addition to differences in the experimental designs, metabolic differences between animals and human cannot be discarded.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.